leisure time -WSS

leisure time

author：hotspot 2025-09-28 15:55:16 - browse：6

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Medicare Advantage today, explained in one chart

hotspot

focus

WSS

NIH director takes cautious approach to Biden drug pricing priority

Medicare Advantage today, explained in one chart

How digital therapeutics firms are pivoting after Pear's bankruptcy

How digital therapeutics firms are pivoting after Pear's bankruptcy

Grail faces three suits alleging harassment, retaliation

Eli Lilly, Pfizer, and others want in on the online prescription market

Wikipedia

leisure time

explore

Peter Hotez and the public health issue of online harassment

Does aspartame cause cancer? What new WHO guidance says

As demand for Covid shots wanes, Moderna seeks its next success

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Walensky prepares to leave CDC — and Congress — behind

Eli Lilly, Pfizer, and others want in on the online prescription market

Dobbs anniversary: the lost opportunity of abortion as health care

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Dobbs anniversary: the lost opportunity of abortion as health care

Celiac disease study examines precisely how gluten triggers injury

focus

The surgeon had a dilemma only a Nazi medical text could resolve

My yearlong odyssey to get my son’s ADHD medication covered

Biotech venture capitalists face new demands from investors

Global childhood vaccinations edge closer to pre

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Francis Collins on trust in science and how Covid communications failed

knowledge

hotspot

focus

hotspot